FindTrial
Sign In

Intravenous Labetalol Versus Hydralazine in Preeclampsia

The Effect of Intravenous Infusion of Labetalol Versus Hydralazine on Cerebral Hemodynamics of Preeclampsia Patients Prospective Randamized Study

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06360601
Enrollment
40
Registered
2024-04-11
Start date
2024-04-01
Completion date
2024-12-20
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia Severe

Brief summary

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Interventions

DRUGLabetalol Injection

Labetalol intravenous infusion 20ml/hr

DRUGHydrALAZINE Injection

Hydralazine intravenous infusion 5mg/hr

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* patient with clinical diagnosis of sever preeclampsia

Exclusion criteria

Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion \-

Design outcomes

Primary

MeasureTime frameDescription
Cerebral blood flowPre intervention-after one hour of interventionMean cerebral blood flow and cerebral perfusion pressure

Countries

Egypt

Contacts

Primary Contactshimaa zahraa
Meikamal89@outlook.com201550273707

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026